University Medical Center Clinical Trials
-
-
Principal Investigator
Agustin Garcia, MD
-
Category
Oncology - Female Reproductive
-
Title of Protocol
A Phase 1/2a Evaluation of the Safety and Efficacy of Adding AL3818, a Dual Receptor Tyrosine Kinase Inhibitor, to Standard Platinum-Based Chemotherapy in Subjects with Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma.
- Brief Description
-
Research Phone
# 504.407.7395
-
Principal Investigator
-
-
Principal Investigator
Agustin Garcia, MD
-
Category
Oncology - Breast
-
Title of Protocol
A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-1-positive metastatic breast cancer.
- Brief Description
-
Research Phone
# 504.407.7395
-
Principal Investigator
-
-
Principal Investigator
Agustin Garcia, MD
-
Category
Oncology - Cervical
-
Title of Protocol
A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety Using Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Recurrent, Metastatic, or Persistent Cervical Carcinoma.
- Brief Description
-
Research Phone
# 504.407.7395
-
Principal Investigator
-
-
Principal Investigator
Agustin Garcia, MD
-
Category
Oncology - Melanoma/Breast
-
Title of Protocol
A Multicenter, Open-label, Phase 2 Study of Imprime PGG and Pembrolizumab in Subjects With Advanced Melanoma Failing Front-line Treatment with Checkpoint Inhibitors (CPI) or Triple Negative Breast Cancer (TNBC) Failing Front-line Chemotherapy for Metastatic Disease.
- Brief Description
-
Recruitment Contact
Research Phone
# 504.407.7395
-
Principal Investigator
-
-
Principal Investigator
Augusto Ochoa, MD
-
Category
Oncology - Breast
-
Title of Protocol
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Capecitabine in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy.
- Brief Description
-
Recruitment Contact
Research Phone
# 504.407.7395
-
Principal Investigator
-
-
Principal Investigator
Augusto Ochoa, MD
-
Category
Oncology - Multiple
-
Title of Protocol
S1609: DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors Treatment with Ipilimumab and Nivolumab for Rare Cancers
- Brief Description
-
Recruitment Contact
Research Phone
# 504.407.7395
-
Principal Investigator
-
-
Principal Investigator
Augusto Ochoa, MD
-
Category
Oncology - Breast/ Gynecologic
-
Title of Protocol
NRG-CC004 Phase Ii Double Blind Dose Finding Trial of Bupropion Versus Placebo For Sexual Desire In Women With Breast Or Gynecologic Cancer.
- Brief Description
-
Recruitment Contact
Research Phone
# 504.407.7395
-
Principal Investigator
-
-
Principal Investigator
Augusto Ochoa, MD
-
Category
Oncology - Melanoma
-
Title of Protocol
A Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients with Advanced BRAFV600 Mutant Melanoma.
- Brief Description
-
Recruitment Contact
Research Phone
# 504.407.7395
-
Principal Investigator
-
-
Principal Investigator
Augusto Ochoa, MD
-
Category
Oncology - Renal
-
Title of Protocol
S1500; A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET).
- Brief Description
-
Recruitment Contact
Research Phone
# 504.407.7395
-
Principal Investigator
-
-
Principal Investigator
Augusto Ochoa, MD
-
Category
Oncology - Pancreatic
-
Title of Protocol
S1505; A Randomized Phase II Study of Perioperative mFOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma.
- Brief Description
-
Recruitment Contact
Research Phone
# 504.407.7395
-
Principal Investigator
-
-
Principal Investigator
Augusto Ochoa, MD
-
Category
Oncology - Melanoma
-
Title of Protocol
EA6141 Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma.
- Brief Description
-
Recruitment Contact
Research Phone
# 504.407.7395
-
Principal Investigator
-
-
Principal Investigator
Augusto Ochoa, MD
-
Category
Oncology - Breast
-
Title of Protocol
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer.
- Brief Description
-
Recruitment Contact
Research Phone
# 504.407.7395
-
Principal Investigator
-
-
Principal Investigator
Cindy Leissinger, MD
-
Category
Hematology - Hemophilia
-
Title of Protocol
An Open-Label, Multicenter, Expanded Access Program For Emicizumab in Patents With Hemophilia and With Inhibitors.
- Brief Description
-
Recruitment Contact
Melody Benton:
mbenton@tulane.edu
or 504.988.3596
-
Principal Investigator
-
-
Principal Investigator
David Janz, MD
-
Category
Pulmonology
-
Title of Protocol
VIOLET: Vitamin D to Improve Outcomes by Leveraging Early Treatment.
- Brief Description
-
Recruitment Contact
Paula Lauto:
plauto@lsuhsc.edu
or 504.568.4634
-
Principal Investigator
-
-
Principal Investigator
Frank Smart, MD
-
Category
Cardiology
-
Title of Protocol
Medtronic Reveal LINQ Heart Failure Study
- Brief Description
-
Recruitment Contact
Jacob Simon:
jsimo9@lsuhsc.edu
or 504.568.2349
-
Principal Investigator
-
-
Principal Investigator
Frank Smart, MD
-
Category
Cardiology
-
Title of Protocol
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to
Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects With Chronic Heart Failure With Reduced Ejection Fraction. - Brief Description
-
Recruitment Contact
Jacob Simon:
jsimo9@lsuhsc.edu
or 504.568.2349
-
Principal Investigator
-
-
Principal Investigator
Frank Smart, MD
-
Category
Cardiology
-
Title of Protocol
A phase III randomised, double-blind trial to evaluate efficacy and safety of once daily empagliflozin 10 mg compared to placebo, in patients with chronic Heart Failure with preserved Ejection Fraction (HFpEF)- EMPEROR-Preserved.
- Brief Description
-
Recruitment Contact
Jacob Simon:
jsimo9@lsuhsc.edu
or 504.568.2349
-
Principal Investigator
-
-
Principal Investigator
Juzar Ali, MD
-
Category
Pulmonology
-
Title of Protocol
An Open-Label Safety Extension Study to a Multicenter Study of Liposomal Amikacin for Inhalation (LAI) in Adult Patients with Nontuberculous Mycobacterial (NTM) Lung Infections Caused by Mycobacterium avium complex (MAC) That are Refractory to Treatment.
- Brief Description
-
Recruitment Contact
Maureen Vincent:
mvince@lsuhsc.edu
or 504.568.4581
-
Principal Investigator
-
-
Principal Investigator
Jyotsna Fuloria, MD
-
Category
Oncology - Pancreatic
-
Title of Protocol
A Phase II Multi-Center Study of SM-88 in Subjects with Pancreatic Cancer Whose Disease Has Progressed or Recurred after/on First Line Chemotherapy
- Brief Description
-
Recruitment Contact
Shana Lennard:
shana.lennard@lcmchealth.org
or 504.702.5171
-
Principal Investigator
-
-
Principal Investigator
Jyotsna Fuloria, MD
-
Category
Hematology - Sickle Cell
-
Title of Protocol
A Phase 3, Double-blind, Randomized, Placebo-controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease.
- Brief Description
-
Recruitment Contact
Shana Lennard:
shana.lennard@lcmchealth.org
or 504.702.5171
-
Principal Investigator
-
-
Principal Investigator
Jyotsna Fuloria, MD
-
Category
Oncology - Relapsed of Refractory Multiple Myeloma and Relapsed or Refractory Acute Myeloid Leukemia
- Title of Protocol
-
A Phase 1 First in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects With Relapsed or Refractory Multiple Myeloma and Subjects With Relapsed or Refractory Acute Myeloid Leukemia
- Brief Description
-
Recruitment Contact
Shana Lennard:
shana.lennard@lcmchealth.org
or 504.702
-
Principal Investigator
-
-
Principal Investigator
Jyotsna Fuloria, MD
-
Category
Oncology - Non-Small Cell Lung Cancer
-
Title of Protocol
Randomized, Open-Label, Phase 3 Trial of Nivolumab plus Ipilimumab or Nivolumab plus Platinum-Doublet Chemotherapy versus Platinum-Doublet Chemotherapy in Early Stage NSCLC.
- Brief Description
-
Recruitment Contact
Shana Lennard:
shana.lennard@lcmchealth.org
or 504.702
-
Principal Investigator
-
-
Principal Investigator
Kara De Felice, MD
-
Category
Gastroenterology
-
Title of Protocol
An Open-Label, Phase 4 Study to Evaluate the Efficacy and Safety of Triple Combination Therapy with the Vedolizumab IV, Adalimumab SC, and Oral Methotrexate in Early Treatment of Subjects with Crohn's Disease Stratified at Higher Risk for Developing Complications.
- Brief Description
-
Recruitment Contact
Marie Sandi, FNP-BC:
mchild@lsuhsc.edu
or 504.568.3450
-
Principal Investigator
-
-
Principal Investigator
Matthew Lammi, MD
-
Category
Pulmonology
-
Title of Protocol
TRITON: The efficacy and safety of initial triple versus initial dual oral combination therapy in patients with newly diagnosed pulmonary arterial hypertension: A multi-center, double-blind, placebo-controlled, Phase 3b study
- Brief Description
-
Recruitment Contact
Paula Lauto:
plauto@lsuhsc.edu
or 504.568.4634
-
Principal Investigator
-
-
Principal Investigator
Michael Hagensee, MD
-
Category
Infectious Disease
-
Title of Protocol
ANCHOR: Anal Cancer/HSIL Outcomes Research Study
- Brief Description
-
Recruitment Contact
Cara Rowe, MSW: cjoh26@lsuhsc.edu
or 504.568.4640
-
Principal Investigator
-
-
Principal Investigator
Michael Hagensee, MD
-
Category
Infectious Disease
-
Title of Protocol
SYN-078-301: Open-Label Study to Evaluate the Efficacy and Safety of SCY-078 in Patients with Fungal Diseases that are Refractory to or Intolerant of Standard Antifungal Treatment
- Brief Description
-
Recruitment Contact
Cara Rowe, MSW:
cjoh26@lsuhsc.edu
or 504.568.4640
-
Principal Investigator
-
-
Principal Investigator
Michelle Loch, MD
-
Category
Oncology - Breast
-
Title of Protocol
A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase II Study of the Efficacy and Safety of Trastuzumab Emtansine in Combination with Atezolizumab or Placebo in Patients with HER-Positive Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Trastuzumab and Taxane based Therapy (Main)
- Brief Description
-
Recruitment Contact
Research Phone
# 504.407.7395
-
Principal Investigator
-
-
Principal Investigator
Nathan Nielsen, MD
-
Category
Pulmonolgy/Critical Care
-
Title of Protocol
LJ501-EAP01 EXPANDED ACCESS FOR LJPC-501
- Brief Description
-
Recruitment Contact
Nathan Nielsen, MD:
nnielsen@tulane.edu
or 504.988.3833
-
Principal Investigator
-
-
Principal Investigator
Oren Tessler, MD
-
Category
Plastic Surgery
-
Title of Protocol
MTF 16-04-01: A Prospective, Randomized, Multi-Center Clinical Study Comparing Outcomes in Patients Undergoing, Prosthetic Acellular Dermal Matrix (ADM) Assisted Immediate Post-Mastectomy Breast Reconstruction.
- Brief Description
-
Recruitment Contact
Allison Fleury, RN:
afleur@lsuhsc.edu
or 504.903.9000
-
Principal Investigator
-
-
Principal Investigator
Patrick Greiffenstein, MD
-
Category
Surgery
-
Title of Protocol
ACCUTE ATB-202 A Phase III Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study of AB103 as Compared to Placebo in Patients with Necrotizing Soft Tissue Infections (NSTI)
- Brief Description
-
Recruitment Contact
Allison Fleury, RN: afleur@lsuhsc.edu
or 504.903.9000
-
Principal Investigator
-
-
Principal Investigator
Patrick Greiffenstein, MD
-
Category
Surgery
-
Title of Protocol
An Open-Label Study to Evaluate the Efficacy and Safety of Avatrombopag for the Treatment of Subjects with Thrombocytopenia Scheduled for a Surgical Procedure
- Brief Description
-
Recruitment Contact
Allison Fleury, RN:
afleur@lsuhsc.edu
or 504.903.9000
-
Principal Investigator
-
-
Principal Investigator
Reinhold Munker, MD
-
Category
Oncology - Myeloma
-
Title of Protocol
Randomized Phase III Trial of Lenalidomide versus Observation Alone
in Patients with Asymptomatic High-Risk Smoldering Multiple Myeloma - Brief Description
-
Recruitment Contact
Rachel Cruthirds:
rcruthir@tulane.edu
-
Principal Investigator
-
-
Principal Investigator
Reinhold Munker, MD
-
Category
Oncology - Multiple
-
Title of Protocol
[766413-1] EAY131: Molecular Analysis for Therapy Choice (MATCH)
- Brief Description
-
Recruitment Contact
Rachel Cruthirds:
rcruthir@tulane.edu
-
Principal Investigator
-
-
Principal Investigator
Tammuella Singleton, MD
-
Category
Hematology - Hemophilia
-
Title of Protocol
An Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein (rFIXFc; BIIB029) in the Prevention and Treatment of Bleeding in Previously Untreated Patients With Severe Hemophilia B
- Brief Description
-
Recruitment Contact
Melody Benton:
mbenton@tulane.edu
or 504.988.3596
-
Principal Investigator
-
-
Principal Investigator
Tammuella Singleton, MD
-
Category
Hematology - Hemophilia
-
Title of Protocol
An open-label single-arm multicentre non-controlled phase 3a trial investigating safety and efficacy of N8-GP in prophylaxis and treatment of bleeding episodes in previously untreated paediatric patients with severe haemophilia A.
- Brief Description
-
Recruitment Contact
Melody Benton:
mbenton@tulane.edu
or 504.988.3596
-
Principal Investigator
-
-
Principal Investigator
Thomas Reske, MD
-
Category
Oncology - Liver
-
Title of Protocol
A Phase III Study of Pembrolizumab (MK-3475) vs. Best Supportive Care as 2nd-Line Therapy in Subjects with Previously Systemically Treated Advanced Hepatocellular Carcinoma.
- Brief Description
-
Recruitment Contact
Research Phone
# 504.407.7395
-
Principal Investigator
There are no Events to display.